Dendrite acquires Optas in $12 million deal

Share this article:
Pharma sales force effectiveness firm Dendrite announced that it has acquired relationship marketing firm Optas. The acquisition is valued at $12 million and will be funded by cash, Dendrite said in a statement.
Optas will be rebranded as "Optas: A Divison of Dendrite International."
A Dendrite spokeswoman told MM&M that no jobs will be eliminated as a result of the deal and key management posts on both sides of the deal will remain the same for the foreseeable future.
"Our combined offering will enable pharma companies to reach physicians and patients with consistent messaging and campaigns driven by deep patient and physician knowledge," said Stephen Smith, chief executive of Optas, in a statement.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.